Legal Opinion
Federal Trade Commission v. Watson Pharmaceuticals, Inc.
Court of Appeals for the Eleventh Circuit
Decided April 25, 2012No. 10-12729PublishedCited by 28 opinions
1Opinion of the Court
CARNES, Circuit Judge:
The system of developing new drugs in this country exemplifies the maxims “no risk, no reward” and “more risk, more reward.” Developing new drugs is a risky, lengthy, and costly endeavor, but it also can be highly lucrative. Only one in every 5,000 medicines tested for the potential to treat illness is eventually approved for patient use, and studies estimate that developing a new drug takes 10 to 15 years and costs more than $1.3 billion. 1 No rational actor would take that kind of a risk over that period of time without the prospect of a big reward. The reward, if any,…
2Cases cited25 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Larry Bonner v. City of Prichard, AlabamaCourt of Appeals for the Eleventh Circuit · 1981
- Whitmore Ex Rel. Simmons v. ArkansasSupreme Court of the United States · 1990
- Christianson v. Colt Industries Operating Corp.Supreme Court of the United States · 1988
20 more not listed; retrieve them via the Exa API.
3Cited by28 opinions
- F.T.C. v. Actavis, Inc.Supreme Court of the United States · 2013
- James Freeman v. Pittsburgh Glass Works LLCCourt of Appeals for the Third Circuit · 2013
- Federal Trade Commission v. Abbvie Products LLCCourt of Appeals for the Eleventh Circuit · 2013
- In Re Wellbutrin XL Antitrust Litigation Indirect Purchaser ClassCourt of Appeals for the Third Circuit · 2017
- In Re Lipitor Antitrust LitigationCourt of Appeals for the Third Circuit · 2017
23 more not listed; retrieve them via the Exa API.